Home pageIMRN โข NASDAQ
add
Immuron Ltd - ADR
Chiusura precedente
1,98ย $
Intervallo giornaliero
1,89ย $ - 1,91ย $
Intervallo annuale
1,59ย $ - 5,96ย $
Cap di mercato
17,63ย Mln AUD
Volume medio
6600,00
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
| (AUD) | giu 2024info | Variazione Y/Y |
|---|---|---|
Entrate | 1,27ย Mln | 108,61% |
Spese di gestione | 2,56ย Mln | 79,40% |
Utile netto | -2,43ย Mln | -169,00% |
Margine di profitto netto | -190,94 | -28,94% |
Utili per azione | โ | โ |
EBITDA | -1,68ย Mln | -118,52% |
Aliquota fiscale effettiva | โ | โ |
Stato patrimoniale
Totale attivo
Totale passivo
| (AUD) | giu 2024info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 11,66ย Mln | -32,07% |
Totale attivo | 15,55ย Mln | -29,28% |
Totale passivo | 2,84ย Mln | 19,79% |
Patrimonio netto totale | 12,71ย Mln | โ |
Azioni in circolazione | 228,00ย Mln | โ |
Prezzo/valore contabile | 33,00 | โ |
Redditivitร dell'attivo | -27,02% | โ |
Rendimento sul capitale | -32,61% | โ |
Flusso di cassa
Flusso di cassa netto
| (AUD) | giu 2024info | Variazione Y/Y |
|---|---|---|
Utile netto | -2,43ย Mln | -169,00% |
Liquiditร di esercizio | -1,94ย Mln | -141,79% |
Contanti da investimenti | 87.027,00 | 1.082,80% |
Contanti da finanziamenti | 12.000,00 | 203,57% |
Flusso di cassa netto | -1,78ย Mln | -170,36% |
Flusso di cassa libero | -1,03ย Mln | -197,20% |
Informazioni
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Fondazione
1994
Sito web
Dipendenti
7
